HWG Holdings LP bought a new stake in shares of PRA Health Sciences Inc (NASDAQ:PRAH) in the third quarter, HoldingsChannel reports. The institutional investor bought 53,710 shares of the medical research company’s stock, valued at approximately $5,918,000. PRA Health Sciences comprises 4.0% of HWG Holdings LP’s portfolio, making the stock its 7th biggest holding.

Several other large investors also recently added to or reduced their stakes in PRAH. Dimensional Fund Advisors LP lifted its position in shares of PRA Health Sciences by 0.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 444,854 shares of the medical research company’s stock valued at $36,905,000 after acquiring an additional 1,593 shares during the period. Barclays PLC lifted its position in shares of PRA Health Sciences by 119.1% during the 1st quarter. Barclays PLC now owns 17,453 shares of the medical research company’s stock valued at $1,448,000 after acquiring an additional 9,489 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of PRA Health Sciences by 16.5% during the 1st quarter. Cubist Systematic Strategies LLC now owns 9,420 shares of the medical research company’s stock valued at $781,000 after acquiring an additional 1,333 shares during the period. Atlantic Trust Group LLC lifted its position in shares of PRA Health Sciences by 4.8% during the 1st quarter. Atlantic Trust Group LLC now owns 169,971 shares of the medical research company’s stock valued at $14,101,000 after acquiring an additional 7,738 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its position in shares of PRA Health Sciences by 59.2% during the 1st quarter. Xact Kapitalforvaltning AB now owns 7,530 shares of the medical research company’s stock valued at $625,000 after acquiring an additional 2,800 shares during the period. Hedge funds and other institutional investors own 98.82% of the company’s stock.

PRA Health Sciences stock opened at $102.26 on Friday. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.33. PRA Health Sciences Inc has a 52 week low of $76.39 and a 52 week high of $112.88. The firm has a market cap of $6.65 billion, a PE ratio of 29.01, a price-to-earnings-growth ratio of 1.52 and a beta of 0.51.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, August 1st. The medical research company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.12. PRA Health Sciences had a return on equity of 24.52% and a net margin of 4.25%. The company had revenue of $722.84 million during the quarter, compared to analysts’ expectations of $706.57 million. During the same quarter in the previous year, the firm earned $0.79 EPS. PRA Health Sciences’s revenue was up 35.4% on a year-over-year basis. As a group, research analysts forecast that PRA Health Sciences Inc will post 3.89 EPS for the current year.

In other news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the business’s stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $101.01, for a total transaction of $656,565,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

A number of research firms have recently weighed in on PRAH. Evercore ISI began coverage on PRA Health Sciences in a research report on Thursday, October 4th. They set an “inline” rating and a $120.00 target price for the company. Robert W. Baird upped their target price on PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Tuesday, September 11th. BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 25th. SunTrust Banks upped their target price on PRA Health Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, August 3rd. Finally, KeyCorp reiterated a “buy” rating and set a $115.00 target price on shares of PRA Health Sciences in a research report on Thursday, August 2nd. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. PRA Health Sciences currently has an average rating of “Buy” and a consensus target price of $110.50.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Yield Curve

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.